|
|
||||
 |
B |
|||
 |
|
|||
 |
||||
 |
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF™, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Company has four issued patents; one in the U.S., Australia, Russia, and China, and pending patents in 19 other countries. Histo-RECAF™, developed and ready for sale, is a biopsy kit designed as a staining test for AFP receptors. BioCurex has licensed to Abbott Laboratories on a semi-exclusive basis certain aspects of its serum based RECAF™ technology. Abbott has plans to develop the test into a blood based cancer diagnostic test for use in its Architect® system. In the United States in 2004, more than 170 million cancer screening and diagnostic oncology procedures were performed with about 80 million tests representing approximately $9.8 billion. The worldwide market last year was $25.75 billion for cancer diagnostics. The market is expected to grow over 30% during the next four years. The Company recognizes that its RECAF technology can be utilized not only for in-vitro diagnosis but also for imaging and immunotherapy. The use of RECAF for imaging is under further investigation, research and development. The concept is to use a radioisotope to "label" a substance which then localizes on RECAF. Since RECAF is present on cancer cells but not on normal cells, the substance will identify the location of the cancer within the body. An image would then be taken to localize that cancer. The potential for this aspect of the technology to assist both diagnostics and ultimately therapeutics is significant, since knowing the location of the cancer is a further step in effective and early cancer management. We anticipate significant advancement in the imaging arena in the near term. BioCurex's ultimate goal is to provide directed therapy for cancer. The concept is to target the cancer cells expressing RECAF with our antibodies, either by themselves or coupled to chemotherapy drugs, toxins or radioactive compounds. Thus, only RECAF-positive cells, that is, cancer cells, would be killed; normal RECAF-negative cells would be spared. Preliminary in-vitro results suggest that this can be done, but further studies are required before making any definitive claims. |
|||
 |
||||
 |
||||
 |
||||
 |
||||
| GO BACK | ||||
| . | . | |||
